COMMUNIQUÉS West-GlobeNewswire

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
09/04/2026
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S [...]
AMN Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026
09/04/2026
DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook on Thursday, May [...]
Weight Watchers Announces Board Committee Appointments
09/04/2026
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced the following updates to the [...]
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
09/04/2026
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to [...]
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
09/04/2026
Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline [...]
Seres Therapeutics to Present at CARB-X Investor Day
09/04/2026
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X [...]
Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
09/04/2026
Results from the first-ever randomized control trial for the REGENETEN Implant in partial - thickness rotator cuff repair Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces [...]
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
09/04/2026
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive DIFS [...]
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
09/04/2026
Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and explainable AI for trial design in psychedelic clinical development. TORONTO, April 09, 2026 (GLOBE [...]
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
09/04/2026
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m [...]
Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
09/04/2026
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain cancer model that [...]
Losing Your Voice? Millions Experience Persistent Problems Each Year
09/04/2026
ASHA Shares Warning Signs of Voice Disorders and Tips To Protect Your Voice for World Voice Day Rockville, MD, April 09, 2026 (GLOBE NEWSWIRE) -- Most people will experience an occasional sore throat related to a cold [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
09/04/2026
NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig ( [...]
Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
09/04/2026
First patient dosed in France, expanding the DOMISOL study beyond Australia DT ‑ 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program MONTREAL and [...]
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
09/04/2026
• Ecuador aims to become one of the first rabies free countries in Latin America. • Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance. • Boehringer [...]
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
09/04/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global [...]
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
09/04/2026
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage [...]
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
09/04/2026
Strengthens three community health models spanning community‑embedded care, earlier intervention and data ‑ driven population health Scales program footprint from 11 countries to more than 30 by 2030, including across [...]
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
09/04/2026
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical [...]

Pages